News

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company addressing the cognitive, behavioral, and functional components of dementia, recently announced that two presentations on the company’s drug development efforts have been accepted for the 2015 International Conference of the Alzheimer’s Association (AAIC) that will take place in Washington, D.C. from the…

Researchers at Newcastle University in the United Kingdom recently revealed their findings on alterations in the brain network of patients with disorders linked to dementia, namely dementia with Lewy bodies (DLB) and Alzheimer’s disease. The study was published in the journal Neurobiology of Aging and is…

In a recent study published in the Journal of Neuroinflammation, researchers from China were able to identify a new target to address the Neuroinflammation found in patients with Alzheimer’s disease. Neuroinflammation, characterized by excessive glial activation and overproduction of proinflammatory cytokine and chemokines, plays a critical…

The summer solstice is the longest day of the year, and it is not just for baseball games and backyard barbecues. Every year on the summer solstice, the Alzheimer’s Association hosts “The Longest Day,” which is a team event to raise awareness and funds for Alzheimer’s. This year, teams from all…

Type 2 diabetes is a condition that normally occurs in late adulthood, and patients with the disease are at increased risk for dementia when compared to non-diabetics. In a recent study, Michael…

UK-based Dementia Consortium announced that it will grant £500,000 ($790,000) in funding to a collaborative research effort that includes academics from the University of Southampton and drug discovery specialists from the medical research charity MRC Technology. The newly-funded project will focus on targeting the immune system in order to develop new therapeutic options to treat Alzheimer’s disease.

A study published in the latest edition of the journal PLOS Medicine used gene variant analysis to assess the association between modifiable risk factors and individual patient susceptibility to being diagnosed with Alzheimer’s Disease (AD).  The study, entitled “Associations between Potentially Modifiable Risk Factors…

Researchers at the Hospital de Magalhães Lemos and the Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto in Portugal recently revealed that a patient’s ability to cope with the neurodegenerative process in disorders like Alzheimer’s disease can influence disease severity. The study is entitled “…

Actinogen Limited, a biotechnology company focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia, recently announced that it has received approval for the third and final stage of the second…

The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Stemedica Cell Technologies, Inc. The approval means that the company is allowed to initiate a phase 2a clinical study to evaluate the use of an allogeneic stem-cell therapy for…